inflammatory diseases news from FierceBiotech
News
Novo to open development ops in Seattle
Novo Nordisk's push to explore new therapeutic areas has brought it to Seattle, WA, where the Danish company plans to open a research center. The developer, which is known for its diabetes drugs, is... Read more...
GSK collaborates on immune disease research
GlaxoSmithKline has inked a five year, $25 million collaboration deal with the Disease Institute of Boston to conduct on immunoinflammation research. GSK and IDI researchers will develop joint grant... Read more...
Inimex raises $22M in VC
Despite a recent Ernst & Young report on the funding challenges in Canada, Inimex... Read more...
SPOTLIGHT: Array lands $80M financing deal
Deerfield Management will provide $80 million to Array BioPharma to fund its drug discovery work. Array is advancing new therapies for inflammatory diseases and cancer. Principal and interest of 6.5... Read more...
Rituxan fails (again) in late-stage lupus trial
Genentech and Biogen Idec were taking it on the chin this morning after researchers announced that Rituxan had failed in a later-stage trial as a therapy for lupus. The failure won't harm the... Read more...
SPOTLIGHT: Biocon establishing R&D sub
India's Biocon says it will transfer four molecules to a new R&D subsidiary, resisting a trend in the subcontinent of spinning off R&D into a new company. Its researchers are working on new... Read more...
Dyax forges $231M development deal for DX-88
Cubist Pharmaceuticals has agreed to pay Dyax $15 million upfront and up to $216.5 million more in potential milestone payments for collaboration rights to Dyax's experimental therapy for the... Read more...
ALSO NOTED: FDA approves UCB's Cimzia; MacroChem acquires Virium; and much more...
> The FDA has approved UCB's monoclonal antibody Cimzia for the treatment of moderate to severe Crohn's disease. Cimzia's approval was Read more...
Resolvyx rounds up $25M
Bedford, MA-based Resolvyx has garnered $25 million in a second round of venture capital. QVT Financial LP led the funding round. The money will be used to accelerate Resolvyx's preclinical... Read more...
GSK tests the miRNA waters with $600M deal
Further solidifying RNA's "next big thing" status, GlaxoSmithKline and Regulus... Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
